Cencora’s first quarter results came in below Wall Street’s revenue expectations, and the market responded negatively. Management pointed to several factors behind the underperformance, including faster-than-expected brand-to-biosimilar conversions at a large mail order pharmacy customer, impacts from recent manufacturer price reductions, and lingering effects from the loss of certain customers. CEO Robert Mauch emphasized the resilience of Cencora’s business model, noting ongoing growth in specialty pharmaceuticals and the positive impact of recent acquisitions such as OneOncology, despite these transitory headwinds.
Is now the time to buy COR? Find out in our full research report (it’s free for active Edge members).
Cencora (COR) Q1 CY2026 Highlights:
- Revenue: $78.36 billion vs analyst estimates of $81.51 billion (3.8% year-on-year growth, 3.9% miss)
- Adjusted EPS: $4.75 vs analyst expectations of $4.73 (in line)
- Adjusted EBITDA: $1.40 billion vs analyst estimates of $1.44 billion (1.8% margin, 3.1% miss)
- Management slightly raised its full-year Adjusted EPS guidance to $17.78 at the midpoint
- Operating Margin: 1.5%, in line with the same quarter last year
- Market Capitalization: $50.77 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Cencora’s Q1 Earnings Call
- Lisa Gill (JPMorgan) asked how operating profit is affected by revenue headwinds such as biosimilar conversions and manufacturer price reductions; CFO James Cleary explained these mostly impact revenue, not operating profit, due to their lower margin nature.
- Michael Cherny (Leerink Partners) inquired about the risk factors and confidence level in accelerating growth in the second half; Cleary detailed that easier comparisons and ramping contributions from recent acquisitions underpin the improved outlook.
- Glen Santangelo (Barclays) raised concerns about biosimilar adoption affecting specialty profit pools; CEO Robert Mauch clarified that in some channels biosimilar conversions are neutral or positive for profits, particularly in the physician-administered segment (Part B).
- Elizabeth Anderson (Evercore ISI) asked about the ongoing performance and integration of the OneOncology acquisition; Mauch highlighted early synergies and collaboration benefits between OneOncology and RCA under the MSO platform.
- Charles Rhyee (Cowen) probed the impact of mail order conversion speed and whether smaller customer losses were material; Mauch and Cleary reiterated that only large customer changes have a notable effect and most future losses are already considered in guidance.
Catalysts in Upcoming Quarters
In the quarters ahead, the StockStory team will be watching (1) the impact of specialty pharmaceutical growth and MSO integration on operating margins, (2) how quickly mail order brand-to-biosimilar conversions stabilize, and (3) whether international logistics and distribution maintain their recent momentum. The outcome of portfolio optimization efforts, including the MWI Animal Health and Covetrus merger, will also be important to monitor.
Cencora currently trades at $260.20, down from $305.90 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
